Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma
- 15 January 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (2) , 760-768
Abstract
Inappropriate activation of MET, the receptor tyrosine kinase for hepatocyte growth factor (HGF), has been implicated in tumorigenesis. Although we have previously shown that HGF/MET signaling controls survival and proliferation of multiple myeloma (MM), its role in the pathogenesis of other B-cell malignancies has remained largely unexplored. Here, we have examined a panel of 110 B-cell malignancies for MET expression, which, apart from MM (48%), was found to be largely confined to diffuse large B-cell lymphomas (DLBCLs) (30%). No amplification of the MET gene was found; however, mutational analysis revealed 2 germ-line missense mutations: R1166Q in the tyrosine kinase domain in 1 patient, and R988C in the juxtamembrane domain in 4 patients. The R988C mutation has recently been shown to enhance tumorigenesis. In MET-positive DLBCL cells, HGF induces MEK-dependent activation of ERK and PI3K-dependent phosphorylation of PKB, GSK3, and FOXO3a. Furthermore, HGF induces PI3K-dependent α4β1 integrin-mediated adhesion to VCAM-1 and fibronectin. Within the tumor microenvironment of DLBCL, HGF is provided by macrophages, whereas DLBCL cells themselves produce the serine protease HGF activator (HGFA), which autocatalyzes HGF activation. Taken together, these data indicate that HGF/MET signaling, and secretion of HGFA by DLBCL cells, contributes to lymphomagenesis in DLBCL. (Blood. 2006;107:760-768)Keywords
This publication has 68 references indexed in Scilit:
- Prognostic significance of hepatocyte growth factor and c‐MET expression in patients with diffuse large B‐cell lymphomaBritish Journal of Haematology, 2004
- Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activatorBlood, 2004
- The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2Journal of Experimental Medicine, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Scatter-factor and semaphorin receptors: cell signalling for invasive growthNature Reviews Cancer, 2002
- The role of hepatocyte growth factor and its receptor c‐met in interactions between lymphocytes and stromal cells in secondary human lymphoid organsImmunology, 2001
- A novel germ line juxtamembrane Met mutation in human gastric cancerOncogene, 2000
- Cellular Origin of Human B-Cell LymphomasNew England Journal of Medicine, 1999
- Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signalingOncogene, 1999
- Frequent amplification of the c-met gene in scirrhous type stomach cancerBiochemical and Biophysical Research Communications, 1992